VLP Inhibitors
VLP Inhibitors encompass a diverse spectrum of chemical compounds that diminish the functional activity of VLP by targeting specific cellular signaling pathways and biochemical processes. Rapamycin, an mTOR inhibitor, and LY 294002, a PI3K inhibitor, both suppress pathways critical for protein synthesis and cell proliferation, which could indirectly reduce VLP activity if it is reliant on these pathways. Staurosporine, a broad-spectrum protein kinase inhibitor, along with PD 98059 and SB 203580, which are specific inhibitors of MEK and p38 MAPK respectively, may decrease VLP activity by interfering with kinase-mediated signaling pathways that potentially regulate VLP's function. Y-27632, a ROCK inhibitor, and Gö 6983, a PKC inhibitor, could lead to a decline in VLP activity by disrupting cytoskeletal rearrangements and kinase-dependent phosphorylation events, assuming VLP functions intersect with these processes.
Other inhibitors operate by modulating intracellular calcium signaling and second messenger systems, which are crucial for various cellular functions. W-7, a calmodulin antagonist, and BAPTA/AM, a calcium chelator, could lead to an indirect reduction in VLP activity, should VLP be dependent on calcium/calmodulin-mediated pathways. U-73122 inhibits phospholipase C, potentially causing a decrease in VLP activity if it is influenced by the diacylglycerol and inositol trisphosphate signaling pathways. ZM 336372, by inhibiting the RAF/MEK/ERK pathway, and NSC 23766, by disrupting Rac1-dependent signaling, further showcase the diversity of mechanisms through which VLP activity can be indirectly diminished, highlighting their potential in influencing VLP-regulated cellular processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, Rapamycin suppresses the mTOR pathway, which is crucial for protein synthesis and cell growth. By inhibiting mTOR, the functional activity of VLP, which may rely on these cellular processes, is indirectly diminished. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A non-selective protein kinase inhibitor, Staurosporine can indirectly decrease VLP activity by inhibiting kinases that may phosphorylate VLP or its associated proteins, thereby affecting VLP's functional role. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor, Y-27632 prevents the Rho-associated protein kinase from functioning, which may indirectly lead to decreased cytoskeletal rearrangements and subsequently diminish VLP activity if VLP is involved in these pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, LY 294002 hampers the PI3K/Akt signaling pathway which is involved in cell survival and growth. This indirect inhibition could diminish VLP function if VLP is part of or reliant on this pathway for its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor, PD 98059 indirectly leads to the inhibition of the MAPK/ERK pathway. If VLP activity is contingent upon ERK signaling, then the inhibition of this pathway could lead to decreased VLP activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
By inhibiting p38 MAPK, SB 203580 disrupts inflammatory responses and stress-related signaling. If VLP is implicated in these pathways, its activity would be diminished as a consequence of p38 MAPK inhibition. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
A calmodulin antagonist, W-7 inhibits calmodulin-dependent pathways, which could indirectly lead to decreased VLP activity if VLP is regulated by calcium/calmodulin-dependent processes. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
A calcium chelator, BAPTA/AM reduces intracellular calcium levels, potentially diminishing VLP activity if it is regulated by calcium-dependent signaling pathways. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
A PKC inhibitor, Gö 6983 could diminish VLP activity by preventing protein kinase C from phosphorylating substrates that could be involved in the functional pathways of VLP. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $47.00 | 2 | |
A CRAF inhibitor, ZM 336372 may indirectly decrease VLP activity by inhibiting the RAF/MEK/ERK pathway, which could be crucial for VLP's role if it is associated with this signaling cascade. | ||||||